Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients

Aclarion, Inc.

CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.
NIH BACPAC studies (comeBACK, BEST) using Nociscan; enrollment ongoing, expected completion Q2 2024.
CPT Category III codes 0609T and 0611T secured Jan 2021; early commercialization in progress.
39 issued US/international patents plus 13 pending; market opportunity up to $135B low back pain market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.